Therapeutic targeting of the warburg effect in pancreatic cancer relies on an absence of p53 function

Cancer Research

Volumn 75, Issue 16, 2015, Pages 3355-3364

  Rajeshkumar, N V ^a   Dutta, Prasanta ^b   Yabuuchi, Shinichi ^a   De Wilde, Roeland F ^a   Martinez, Gary V ^b   Le, Anne ^a   Kamphorst, Jurre J ^c   Rabinowitz, Joshua D ^c   Jain, Sanjay K ^a   Hidalgo, Manuel ^d   Dang, Chi V ^e   Gillies, Robert J ^b   Maitra, Anirban ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d Structural Biology and Biocomputing Programme   (Spain)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FLUORODEOXYGLUCOSE F 18; FX 11; LACTATE DEHYDROGENASE; PROTEIN P53; PYRUVIC ACID; UNCLASSIFIED DRUG; 3-DIHYDROXY-6-METHYL-7-(PHENYLMETHYL)-4-PROPYLNAPHTHALENE-1-CARBOXYLIC ACID; C12ORF5 PROTEIN, HUMAN; ISOENZYME; LACTATE DEHYDROGENASE 5; LACTIC ACID DERIVATIVE; NAPHTHALENE DERIVATIVE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; MUTANT; NONHUMAN; ONCOLOGICAL PARAMETERS; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WARBURG EFFECT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; NUDE MOUSE; PANCREATIC NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; L-LACTATE DEHYDROGENASE; LACTATES; MALE; MICE, NUDE; MUTATION; NAPHTHALENES; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRUVIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942782924     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0108     Document Type: Article

References (48)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig A.B., Fleshman JM, Matrisian LM. Projecting cancerincidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-21.
2. Thota R, Pauff JM, Berlin JD Treatment of metastatic pancreatic adeno-carcinoma: a review. Oncology 2014; 28: 70-4.
3. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Warburg O. The metabolism of tumors. London: Constable; 1930. p 5-47.
5. Kim JW, Dang CV Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-30.
6. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425-34.
7. Fischer K, Hoffmann P, Voelkl S., Meidenbauer N, Ammer J, Edinger M., et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109: 3812-9.
8. Gottfried E, Kunz-Schughart LA, Ebner S., Mueller-Klieser W, Hoves S, Andreesen R., et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006; 107: 2013-21.
9. Koukourakis MI, Giatromanolaki A, Sivridis E., Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway-a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006; 24: 4301-8.
10. Gatenby RA, Gillies RJ A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008; 8: 56-61.
11. Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc 2007:35-53.
12. Rong Y, Wu W, Ni X., Kuang T, Jin D, Wang D., et al. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol 2013; 34: 1523-30.
13. Sheng SL, Liu JJ, Dai Y.H., Sun XG, Xiong XP, Huang G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J 2012; 279: 3898-910.
14. McCleland ML, Adler AS, Shang Y, Hunsaker T., Truong T, Peterson D, et al An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 2012; 72: 5812-23.
15. Dutta P, Le A, Vander Jagt DL, Tsukamoto T, Martinez GV, Dang C.V., et al. Evaluation of LDH-A and glutaminase inhibition invivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Res 2013; 73: 4190-5.
16. Xie H, Hanai J, Ren J.G., Kats L., Burgess K, Bhargava P, et al Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 2014; 19: 795-809.
17. Wang YH, Israelsen WJ, Lee D, Yu V.W., Jeanson NT, Clish CB, et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 2014; 158: 1309-23.
18. Le A, Cooper CR, Gouw A.M., Dinavahi R., Maitra A, Deck LM, et al Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010; 107: 2037-42.
19. Yen KE, Bittinger MA, Su S.M., Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010; 29: 6409-17.
20. Yang ZJ, Chee CE, Huang S, Sinicrope FA The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10: 1533-41.
21. Rubio-Viqueira B., Jimeno A, Cusatis G., Zhang X, Iacobuzio-Donahue C, Karikari C, et al An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12: 4652-61.
22. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17: 2799-806.
23. Jones S, Zhang X, Parsons D.W., Lin JC, Leary RJ, Angenendt P, et al Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY 2008; 321: 1801-6.
24. Mizuma M, Rasheed ZA, Yabuuchi S, Omura N., Campbell NR, de Wilde RF, et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther 2012; 11: 1999-2009.
25. Favier J, Briere JJ, Burnichon N, Riviere J., Vescovo L, Benit P, et al The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 2009; 4: e7094.
26. Korgun ET, Unek G, Herrera E., Jones CJ, Wadsack C, Kipmen-Korgun D, et al. Mapping of CIP/KIP inhibitors, G1 cyclins D1, D3, E and p53 proteins in the rat term placenta. Histochem Cell Biol 2011; 136: 267-78.
27. Wong PP, Demircioglu F, Ghazaly E., Alrawashdeh W, Stratford MR, Scudamore C.L., et al. Dual-action combination therapy enhances angio-genesis while reducing tumor growth and spread. Cancer Cell 2015; 27: 123-37.
28. Rajendran R, Garva R, Ashour H., Leung T, Stratford I, Krstic-Demonacos M, et al. Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer. Int J Oncol 2013; 42: 1961-72.
29. Weinstein EA, Liu L, Ordonez A.A., Wang H., Hooker JM, Tonge PJ, et al. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother 2012; 56: 6284-90.
30. Hill DK, Orton MR, Mariotti E, Boult J.K., Panek R., Jafar M, et al. Model free approach to kinetic analysis of real-time hyperpolarized 13C magnetic resonance spectroscopy data. PLoS ONE 2013; 8: e71996.
31. Harrison C, Yang C, Jindal A., DeBerardinis RJ, Hooshyar MA, Merritt M, et al Comparison of kinetic models for analysis of pyruvate-to-lactate exchange by hyperpolarized 13 C NMR. NMR Biomed 2012; 25:1286-94.
32. Koukourakis MI, Giatromanolaki A, Sivridis E., Bougioukas G, Didilis V, Gatter K.C., et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89: 877-85.
33. Koukourakis MI, Giatromanolaki A, Sivridis E. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 2003; 24: 199-202.
34. Zhao D, Zou SW, Liu Y, Zhou X., Mo Y, Wang P, et al Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell 2013; 23: 464-76.
35. Kanno T, Sudo K, Maekawa M., Nishimura Y, Ukita M, Fukutake K. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta 1988; 173: 89-98.
36. Whatcott CJ, Diep CH, Jiang P, Watanabe A., LoBello J, Sima C, et al Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res 2015; Feb 18. [Epub ahead of print].
37. Bensaad K, Tsuruta A, Selak M.A., Vidal MN, Nakano K, Bartrons R, et al TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-20.
38. Lee P, Vousden KH, Cheung EC TIGAR, TIGAR, burning bright. Cancer Metab 2014; 2: 1.
39. Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem 2012; 287: 33436-46.
40. Golman K, in 't Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci U S A 2006; 103: 11270-5.
41. Golman K, Zandt RI, Lerche M, Pehrson R., Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006; 66: 10855-60.
42. Day SE, Kettunen MI, Gallagher F.A., Hu DE, Lerche M, Wolber J, et al Detecting tumor response to treatment using hyperpolarized C-13 magnetic resonance imaging and spectroscopy. Nat Med 2007; 13: 1382-7.
43. Hu S, Balakrishnan A, Bok R.A., Anderton B., Larson PE, Nelson SJ, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011; 14:131-42.
44. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt F.C., Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44: 127-39.
45. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-82.
46. Pouyssegur J, Dayan F, Mazure NM Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-43.
47. Lodi A, Woods SM, Ronen SM Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed 2013; 26: 299-306.
48. Zhang C, Liu J, Liang Y., Wu R, Zhao Y, Hong X., et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 2013; 4: 2935.